The thesis
PanicFade v4 bets on a well-documented behavioural quirk: markets overreact to negative headlines, and the ensuing panic tends to revert toward fundamentals. The rules are disciplined rather than clever. It buys names hit by sentiment below -0.4 that are already technically oversold — RSI14 under 35 and trading below their SMA20 — and sizes into the fall. Exits are symmetric: it takes profit on reversion (RSI14 back above 50 or price reclaiming SMA20) and hard-stops fresh lows on continued negativity, treating persistent weakness as a genuine fundamental break rather than a fadeable dip.
The approach is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025, plus corroborating JRFM work), which is a welcome step above the usual curve-fit-and-hope. The universe is deliberately conservative — 24 mega-cap and large-cap names across tech, financials, healthcare, staples and energy — which limits liquidity risk and keeps the reversion assumption defensible.
What the numbers say
The full backtest returns 37.93% over 1,233 days, with a 62.88% win rate across 530 trades and a contained 9.3% max drawdown. Read carefully, though: that translates to a 6.79% CAGR and a Sharpe of 0.96 — respectable, not spectacular. Turnover of 5,807% confirms this is a high-churn strategy, and while total fees ($530) stayed modest, that cadence leaves little room for slippage in the real world.
The validation is the stronger story. Across four walk-forward folds, all four were positive, and performance improved monotonically — from a barely-there 1.6% in the 2021–2022 bear leg to 21.7% in the most recent fold, where Sharpe reached 2.44. A Probabilistic Sharpe Ratio of 0.985 and a Deflated Sharpe Ratio of 0.56 across 27 trials suggest the edge survives correction for multiple-testing luck. The DSR is the honest caveat here: above zero and therefore credible, but well short of a slam dunk.
Live reality check
This is where balance matters. Over the last week of scheduled runs, PanicFade v4 mostly did nothing — six consecutive sessions with zero executions before a single buy on 28 August: 10 shares of WMT at $103.115. That inactivity is by design; the entry filter is demanding, and a calm tape simply offers no panic to fade. But it also means the strategy sat in cash while opportunity was scarce, and its one live position nudged total equity to $9,989.69 — a fractional paper loss on day one.
Verdict
PanicFade v4 is one of the more intellectually honest strategies in the stable: a literature-backed thesis, symmetric exits, and a validation regime that actually deflates for trial count. The risks are equally clear. The headline 37.93% masks a single-digit CAGR; the high turnover demands clean execution; and the demanding filter can leave the book idle for stretches, making returns lumpy and dependent on volatility clusters. Watch whether the recent-fold outperformance is a durable edge or a bull-market tailwind. For now: promising, validated, and worth watching — not yet worth betting the firm on.